Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Caso contributivo

PDF MeBrain

Un empiema pleurico, una occasione per fare il punto sulla vaccinazione antipneumococcica

Pleural empyema and the pneumococcal vaccination

Giuliana Ferrante, Luca Alessi, Mario Giuffrè, Giovanni Corsello
Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, Scuola di Specializzazione in Pediatria, Università di Palermo

Dicembre 2020 | DOI: 10.53126/MEBXXIII240

Abstract
The article describes the case of a 4-year-old girl present-ing with fever and dyspnea. Blood tests showed neutrophilic leukocytosis and a significant increase in inflammation markers. The antibiotic therapy (macrolide and amoxicillin) did not produce any clinical improvement. A chest X-ray and CT showed a pleural empyema associated to trilobar right pneumonia. An evacuative videothoracoscopy was then performed. Clinical evolution was positive with full remission. The real-time polymerase chain reaction enabled to isolate genetic sequences of Streptococcus pneumoniae type 3, one of the serotypes involved in the invasive pneumococcal disease and contained in the pneumococcal 13-valent conjugate vaccine (PCV13). The patient had completed a full PCV13 vaccination before two years of age. Despite antibiotic treatment and the spread of vaccinations, pleural empyema is still a frequent complication of pneumonia to date. Several studies suggest a poor effective-ness of the pneumococcal vaccine against the serotype 3. Moreover, the implementation of PCV13 may have influenced the distribution of serotypes of S. pneumoniae not included in this vaccine and the phenomenon of serotype replacement. Nonetheless, the phenomenon of serotype replacement does not seem to be exclusively due to the effect of vaccination programmes.
Riassunto
L’articolo descrive una bambina di 4 anni che giungeva alla nostra osservazione per febbre e dispnea. Gli esami ematici evidenziavano leucocitosi neutrofila e innalzamento significativo degli indici di flogosi. La terapia antibiotica (macrolidi e amoxicillina) non aveva prodotto alcun miglioramento clinico. La radiografia e la TC del torace mostravano un empiema pleurico associato a polmonite trilobare destra. Veniva quindi eseguita una videotoracoscopia evacuativa, a cui faceva seguito la risoluzione del quadro clinico-radiologico. La real-time polymerase chain reaction (RT-PCR) ha permesso di isolare sequenze genetiche di Streptococcus pneumoniae sierotipo 3, uno dei sierotipi coinvolti nella malattia pneumococcica invasiva e contenuto nel vaccino anti-pneumococcico 13-valente (PCV13). La bambina aveva completato la vaccinazione con PVC13 prima dei due anni di età. Nonostante il trattamento antibiotico e la diffusione delle vaccinazioni, l’empiema pleurico è ancora oggi una complicanza frequente della polmonite. Diversi studi suggeriscono una scarsa efficacia del vaccino anti-pneumococcico contro il sierotipo 3. Inoltre l’implementazione del PCV13 può aver influenzato la distribuzione dei sierotipi di S. pneumoniae non inclusi in questo vaccino e il fenomeno del rimpiazzo il quale, tuttavia, non sembra essere esclusivamente ascrivibile all’effetto dei programmi di vaccinazione.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Breasted JH. New York, The Edwin Smith surgical papyrus. v. 2: 41 x 30 cm. [from old catalog]. 1930, Chicago, Ill: The University of Chicago Press. 2 v.
  2. Burgos J, Falcó V, Pahissa A. The increasing incidence of empyema. Curr Opin Pulm Med 2013;19:350-6.
  3. Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis 2007;45:1480-6.
  4. Septimus EJ. Pleural effusion and empyema. In: Mandell GL, Bennet JE, Mandell RD. Douglas and Bennett’s principles and practice of infectious diseases. Edinburgh: Churchill Livingstone 2009, pagg. 917-24.
  5. Canciani M, Don M, del Pin B, et al. Empiema pleurico in Pediatria - L’empiema pleurico nel bambino: un approccio a più voci. Medico e Bambino 2007;26(2):89-102.
  6. Pernica JM, Moldovan I, Chan F, Slinger R. Real-time polymerase chain reaction for microbiological diagnosis of parapneumonic effusions in Canadian children. Can J Infect Dis Med Microbiol 2014;25:151-4.
  7. Obando I, Camacho-Lovillo MS, Porras A, et al. Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009. Clin Microbiol Infect 2012;18:763-8.
  8. Resti M, Moriondo M, Cortimiglia M, et al; Italian Group for the Study of Invasive Pneumococcal Disease. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin Infect Dis 2010;51:1042-9.
  9. Azarian T, Mitchell PK, Georgieva M, et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Patholog 2018;14:e1007438.
  10. Ouldali N, Varon M, Levy C, et al. Invasivve pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interruopted time-series analysis of data from a 17-year national prospective surveillance study. Lancet Infect Dis July 2020 [Epub ahead of print].
  11. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015;15:535-43.
  12. Ladhani SN, Collin S, Diennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales. Lancet Infectious Dis 2018;18:441-51.
  13. Lodi L, Ricci S, Nieddu F, et al. Impact of the 13-valent pneumococcal conjugate vaccine on severe invasive disease caused by serotype 3 Streptococcus pneumoniae in Italian children. Vaccines (Basel) 2019;7(4):128.
  14. Savulescu C, Krizova P, Lepoutre A, et al; SpIDnet group. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med 2017;5:648-56.
  15. European Centre for Disease Prevention and Control. Invasive pneumococcical disease - annual report for 2017. Solna, Sweden: ECDC, 2017.
  16. Rybak A, Levy C, Bonacorsi S, et al. Antibiotic resistance of potential otopathogens isolated from nasopharyngeal flora of children with acute otitis media before, during and after pneumococcal conjugate vaccines implementation. Pediatr Infect Dis J 2018;37:e72-e78.
  17. Corcoran M, Vickers I, Mereckiene J, et al. The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect? Epidemiol Infect 2017;145:2390-9.
  18. Regev-Yochay G, Katzir M, Strahilevitz J, et al; IAIPD group. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation: a nationwide study in Israel. Vaccine 2017;35:2449-56.
  19. Levy C, Varon E, Ouldali N, Béchet S, Bonacorsi S, Cohen R. Changes in invasive pneumococcal disease spectrum after 13-valent pneumococcal conjugate vaccine implementation. Clin Infect Dis 2020;70:446-54.
  20. Fletcher MA, Schmitt HJ, Syrochkina M, Sylvester G. Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology. Eur J Clin Microbiol Infect Dis 2014;33:879-910.
  21. Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect 2018;77:368-78.
  22. Lo SW, Gladstone RA, van Tonder AJ, et al; Global Pneumococcal Sequencing Consortium. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis 2019;19:759-69.
  23. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329-37.
  24. Ouldali N, Cohen R, Levy C, et al. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother 2019;74:3077-86.
  25. Lewnard JA, Hanage WP. Making sense of differences in pneumococcal serotype replacement. Lancet Infect Dis 2019;19:e213-e220.
  26. Tarragó D, Fenoll A, Sánchez-Tatay D, et al. Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR. Clin Microbiol Infect 2008;14:828-34.
  27. Krenke K, Sadowy E, Podsiadły E, Hryniewicz W, Demkow U, Kulus M. Etiology of parapneumonic effusion and pleural empyema in children. The role of conventional and molecular microbiological tests. Respir Med 2016;116:28-33.
  28. Levy C, Ouldali N, Caeymaex L, Angoulvant F, Varon E, Cohen R. Diversity of serotype replacement after pneumococcal conjugate vaccine implementation in Europe. J Pediatr 2019;213:252-3.e3.
  29. Swanson DS, Harrison CJ. Playing “whack-a-mole” with pneumococcal serotype eradication. Pediatrics 2017;140:e20172034.